Dr Helen Keen is a clinical rheumatologist and mid career researcher, having been awarded her PhD (Leeds) in 2011. She is the head of both the South and East Metropolitan Health Services Rheumatology service. She is a foundation member and WA lead of the Western Australia Biobank Committee.
Helen undertook a 3 year fellowship at the University of Leeds, where she had extensive training in clinical trials, outcome methodology, and imaging. She was involved in many clinical trials, with particular relevance to developing outcome tools and optimising outcomes for patients with rheumatic diseases. Helen was the first to systematically investigate the role and validity of US as an imaging outcome tool in osteoarthritis. She is co chair of the international OMERACT (Outcomes MEasures in Rheumatology Clinical Trails) organisation ultrasound working group, contributing to imaging research, her interest remains clinical trials with an interest in RCTs of rheumatic diseases.
With collaborators, she has been awarded over $4 Million in the last 6 years. These include four NHMRC/MRFF grants.
Helen Keen is a committee member of the Fiona Stanley Hospital Research Advisory committee. She is WA president and a Board Member of the Australian Rheumatology Association. She was convenor Australian Rheumatology Association (ARA) annual scientific meeting 2022, Secretary of the ARA Imaging Special Interest Group, ARA representative on the Asia Pacific League Against Rheumatism Ultrasound Special Interest Group, and the Gout Special Interest Group.
